27 reports of this reaction
2.0% of all SELEGILINE HYDROCHLORIDE reports
#9 most reported adverse reaction
DIZZINESS is the #9 most commonly reported adverse reaction for SELEGILINE HYDROCHLORIDE, manufactured by Bausch Health US, LLC. There are 27 FDA adverse event reports linking SELEGILINE HYDROCHLORIDE to DIZZINESS. This represents approximately 2.0% of all 1,332 adverse event reports for this drug.
Patients taking SELEGILINE HYDROCHLORIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for SELEGILINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for SELEGILINE HYDROCHLORIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 27 FDA reports for SELEGILINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.0% of all adverse event reports for SELEGILINE HYDROCHLORIDE, making it a notable side effect.
If you experience dizziness while taking SELEGILINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.